Barclays analyst Gena Wang raised the firm’s price target on Vir Biotechnology (VIR) to $31 from $26 and keeps an Overweight rating on the shares following the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Transformative Year: Earnings Call Insights
- Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology
- Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis
- Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating
- Vir Biotechnology Reports 2024 Financial Results and Strategic Advances